comscoreKeytruda Added to Chemotherapy Improves Overall Survival for Metastatic PD-L1-Positive, Triple-Negative Breast Cancer

Keytruda Added to Chemotherapy Improves Overall Survival for Metastatic PD-L1-Positive, Triple-Negative Breast Cancer

Dr. Hope Rugo discusses final results from the KEYNOTE-355 trial.
Sep 24, 2021
00:00
Download
00:00

Dr. Hope Rugo is a principal investigator of a number of clinical trials looking at combining new targeted and immunotherapy medicines with standard treatments for both early-stage and advanced-stage breast cancer and has published hundreds of peer-reviewed papers.

At the European Society for Medical Oncology Congress 2021, Dr. Rugo presented final results from the KEYNOTE-355 trial, which was looking to see if Keytruda (chemical name: pembrolizumab) and chemotherapy were better than chemotherapy alone as a first treatment for metastatic PD-L1-positive, triple-negative breast cancer. Earlier results found that adding Keytruda to chemotherapy improved progression-free survival — how long people lived before the cancer grew — for this type of breast cancer. These new results show that adding Keytruda improves overall survival — how long people live whether the breast cancer grows or not.

Listen to the podcast to hear Dr. Rugo explain:

  • what the KEYNOTE-355 aimed to do

  • whether Keytruda offers benefits for PD-L1-negative disease

  • why it’s important for a medicine to improve overall survival as well as progression-free survival

  • the differences in PD-L1 tests and what they mean for the effectiveness of breast cancer checkpoint inhibitor medicines

About the guest
 
hope-rugo
Hope S. Rugo, MD

Affiliations: University of California San Francisco Helen Diller Family
Comprehensive Cancer Center, Translational Breast Cancer Research Consortium, Bioasis

Areas of specialization: medical oncology, hematology, breast cancer

Dr. Hope Rugo is a medical oncologist specializing in breast cancer research and treatment. A professor of medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dr. Rugo is the director of the Breast Oncology Clinical Trials
Program.

— Last updated on February 11, 2022, 7:58 PM

 
Lilly Oncology

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate